Pfizer Inc

Pfizer’s 25‑valent pneumococcal vaccine, showing 95% seroconversion in infants, now enters Phase III—offering broader pediatric protection and potential revenue boost.

Pfizer’s 2025 dividend jump, partnership with Mark Cuban to sell Eliquis, and focus on niche therapies show a resilient, investor‑friendly outlook.

Pfizer’s post‑COVID pivot: investing billions in oncology and obesity while juggling FDA scrutiny, dividend stability, and a $150B market opportunity.

Pfizer’s market moves reveal a split investor mood amid a major site shutdown, €1.9 bn legal win, and tariff‑driven cost pressure—how will it steer its future pipeline?

Pfizer’s latest moves: Vanguard’s big buy, Guggenheim’s upgraded target, TALAPRO‑3 results, 6.3% dividend yield – a mixed but bullish snapshot for investors.

Pfizer’s latest news: Phase 3 Lyme vaccine shows 73% efficacy, prostate‑cancer trial could boost shares to $36, and a 6.5% dividend keeps investors bullish.

Pfizer’s 73%‑effective Lyme vaccine hits Phase 3 milestones, sparking regulatory plans but tempered market response as investors weigh commercial prospects and competitive challenges.

Pfizer’s 2026 investor activity shows heavy institutional buying while Medicare price talks loom, hinting at future revenue impacts.

Pfizer’s 2026 earnings miss sparks a sharp shift to “hold” and rising bearish sentiment, as price‑control pressures and safety concerns threaten the pharma giant’s growth legacy.